Join us for insights and practical guidance on the evolving healthcare legal and policy landscape. Our panel of healthcare litigators will discuss current and potential litigation, regulatory developments, and policy shifts shaping strategies for healthcare organizations, life sciences companies, and investors. 

Key topics will include:

• IRA Drug Price Negotiation Challenges: An update on the first wave of litigation challenging the Inflation Reduction Act’s Medicare Drug Price Negotiation Program following the Supreme Court’s denial of cert.
• Mifepristone Litigation: Updates on continued legal challenges to mifepristone access and availability.
• PBM Reform Litigation: Pending and anticipated litigation around pharmacy benefit manager reform.
• 340B Litigation Update: Review of key cases affecting the scope, enforcement, and operations of the 340B Program for covered entities and manufacturers.
• Medicaid Changes in the OBBBA: An overview of disputes relating to the Medicaid-related provisions in the One Big Beautiful Bill Act, including Medicaid work requirements.

Who should attend:

• In-house counsel and compliance leaders at hospitals, health systems, and physician groups.
• Legal, regulatory, and government affairs leaders at health plans and PBMs.
• Life sciences and medtech manufacturers, including market access, pricing, and policy teams.
• 340B covered entities and contract pharmacy leadership.
• Revenue cycle, reimbursement, and government programs professionals.
• Litigation counsel handling healthcare, ERISA, and administrative law matters.
• Investors and advisors focused on healthcare transactions and strategy.

CLE credit for this course is available in New York and California. This program is offering 1.0 Areas of Professional Practice CLE credit in NY, and 1.0 General CLE credit in CA. The program is appropriate for both newly admitted attorneys and experienced attorneys. Please contact us for details.